Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

age oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law. Attachment: Financial
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Calif., March 6 Finesse Solutions, LLC, Santa Clara, ... life sciences process applications, announced the technical demonstration of ... at Interphex in New York on March 17, 2009.The ... consisting of a disposable sheath, an optical reader, and ...
... SEATTLE, March 6 Cell Therapeutics, Inc. (CTI) (Nasdaq ... a letter from The NASDAQ Stock Market indicating that ... the listing of the Company,s common stock on The ... or before April 6, 2009, the Company demonstrate compliance ...
... 6 Irvine Scientific, a leading medical device/biopharmaceutical company ... the addition of IS CHO-CD XP(TM) Culture System to ... Culture System is a set of chemically-defined*, serum-free, and ... deliver robust cell growth and production for recombinant CHO ...
Cached Biology Technology:Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter 2Cell Therapeutics Announces Receipt of NASDAQ Listing Update 2Cell Therapeutics Announces Receipt of NASDAQ Listing Update 3Irvine Scientific Launches IS CHO-CD XP(TM) 2
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The most robust statistical examination to date of our species, ... all living humans -- confirms that she lived about 200,000 ... side-by-side comparison of 10 human genetic models that each aim ... of assumptions about the way humans migrated, expanded and spread ...
... lead to a brand new class of drugs to treat ... back pain without numbing the whole body. The ... (BBSRC) and working at UCL (University College London), have shown ... are regulated by molecules inside cells called small RNAs. This ...
... the best of times, but plants have an extra difficulty. If ... and reproduce, you will want your flowerstalks to be long. That ... But if your stalk is too long, you,ll stand out to ... used to be thought that carnivorous plants like Sundews had the ...
Cached Biology News:Mother of all humans lived 200,000 years ago 2Mother of all humans lived 200,000 years ago 3Scientists uncover Achilles heel of chronic inflammatory pain 2Sundews just want to be loved 2
... difficult to achieve in many bacterial strains ... more restriction and modification (R-M) systems that ... "foreign". TypeOne™ Restriction Inhibitor provides a powerful ... strains with type I R-M systems. ...
... loxP-cm-loxP cassette is designed to ... The prokaryotic promoter gb2 driving ... a slightly modified version of the ... efficiency than the generally used Tn5 ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
... for stabilizing 1.5mg of purified RNA samples., ... the stabilization of aqueous RNA samples that ... as guanidine, phenol/chloroform, silica, oligo dT etc ... contain all the necessary components for the ...
Biology Products: